Serotype dynamics of invasive pneumococcal disease post-PCV7 and pre-PCV13 introduction in North East England

Epidemiology and Infection

Volumn 141, Issue 2, 2013, Pages 344-352

  Chapman, K E ^a   Wilson, D ^a   Gorton, R ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Invasive pneumococcal disease; pneumococcal conjugate vaccine; Streptococcus pneumoniae (pneumococcus)

Indexed keywords

PNEUMOCOCCUS VACCINE;

ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE SURVEILLANCE; GROUPS BY AGE; HUMAN; INCIDENCE; INFECTION PREVENTION; MAJOR CLINICAL STUDY; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; SEROTYPE; UNITED KINGDOM; VACCINATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; ENGLAND; EPIDEMIOLOGICAL MONITORING; HOSPITALIZATION; HUMANS; IMMUNIZATION PROGRAMS; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VACCINES, CONJUGATE;

EID: 84876896959     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268812000763     Document Type: Article

References (27)

1. Hausdorff WP, Feikin DR, Klugman KP. Epidemiological differences among pneumococcal serotypes. Lancet Infectious Diseases 2005; 5: 83-93. (Pubitemid 40174779)
2. Brueggemann AB, et al. Clonal relationships between invasive and carriage Streptococcus pneumoniae and serotype-and clone-specific differences in invasive disease potential. Journal of Infectious Diseases 2003; 187: 1424-1432. (Pubitemid 36549688)
3. Sandgren A, et al. Effect of clonal and serotype-specific properties on the invasive capacity of Streptococcus pneumoniae. Journal of Infectious Diseases 2004; 189: 785-796. (Pubitemid 38328178)
4. Pilishvili T, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. Journal of Infectious Diseases 2010; 201: 32-41.
5. Centres for Disease Control and Prevention. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease-United States, 1998-2003. Morbidity and Mortality Weekly Report 2005; 54: 893-897.
6. Lexau CA, et al. Changing epidemiology of invasive pneumococcal disease among older adults in the era of paediatric pneumococcal conjugate vaccine. Journal of the American Medical Association 2005; 294: 2043-2051. (Pubitemid 41539937)
7. World Health Organisation. Worldwide progress in introducing pneumococcal conjugate vaccine, 2000-2008. Weekly Epidemiological Record 2008; 43: 388-392.
8. Department of Health. Immunization against infectious disease. The Green Book 2010; 25: 295-313.
9. Health Protection Agency. Quarterly vaccination coverage statistics for children aged up to five years in the UK (COVER programme): October to December 2007. Health Protection Report 2008; 2: 13 (http://www.hpa.org.uk/hpr/archives/ 2008/hpr1308.pdf).
10. Director of Immunization, Department of Health. Introduction of Prevenar 131 into the childhood immunization programme, 2010 (http://www.dh.gov.uk/dr- consum-dh/groups/dh-digitalassets/documents/digitalasset/dh-112192.pdf). Accessed 31 August 2011.
11. Office for National Statistics. United Kingdom: Health geography, as at 1 July 2006 (http://www.statistics.gov. uk/geography/downloads/HLTH-JUL-2006%20- UK-MP.pdf). Accessed 31 August 2011.
12. Miller E, et al. Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infectious Diseases 2011; 11: 760-768.
13. Health Protection Agency. Current epidemiology of invasive pneumococcal disease (IPD) (http://www. hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/ Pneumococcal/EpidemiologicalDataPneumococcal/CurrentEpidemiologyPneumococcal/). Accessed 31 August 2011.
14. Huang SS, et al. Continued impact of pneumococcal conjugate vaccine on carriage in young children. Paediatrics. Published online : July 2009. doi:10.1542/peds.2008-3099.
15. De Carvalho Gomes H, et al. Use of seven-valent pneumococcal conjugate vaccine (PCV7) in Europe, 2001-2007. Eurosurveillance 2009; 14(12).
16. Vestrheim DF, et al. Indirect effect of conjugate pneumococcal vaccination in a 2+1 dose schedule. Vaccine 2010; 28: 2214-2221.
17. Harboe ZB, et al. Early effectiveness of heptavalent conjugate pneumococcal vaccination on invasive pneumococcal disease after the introduction in the Danish Childhood Immunization Programme. Vaccine 2010; 28: 2642-2647.
18. Black S. The volatile nature of pneumococcal serotype epidemiology: potential for misinterpretation. Paediatric Infectious Disease Journal 2010; 29: 301-303.
19. O'Brien KL, et al. Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a communityrandomized trial. Journal of Infectious Diseases 2007; 196: 1211-1220. (Pubitemid 47580276)
20. Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet. Published online : 13 April 2011. doi:10.1016/S0140-6736(10)62225-8.
21. Brueggemann AB, et al. Vaccine escape recombinants emerge after pneumococcal vaccination in the United States. PLoS Pathogens 2007; 3: 1628-1636. (Pubitemid 350291600)
22. Trotter CL, et al. Epidemiology of invasive pneumococcal disease in the pre-conjugate vaccine era : England and Wales, 1996-2006. Journal of Infection 2010; 60: 200-208.
23. Jefferies JM, et al. Temporal analysis of invasive pneumococcal clones from Scotland illustrates fluctuations in diversity of serotype and genotype in the absence of pneumococcal conjugate vaccine. Journal of Clinical Microbiology 2010; 48: 87-96.
24. Lepoutre A, et al. Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001-2006. Eurosurveillance 2008; 28(35).
25. Whitney CG, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. New England Journal of Medicine 2003; 348: 1737-1746. (Pubitemid 36514704)
26. Flasche S, Slack M, Miller E. Long term trends introduce a potential bias when evaluating the impact of the pneumococcal conjugate vaccination programme in England and Wales. Eurosurveillance 2011; 16(20).
27. Hammitt LL, et al. Indirect effect of conjugate vaccine on adult carriage of Streptococcus pneumoniae: an explanation of trends in invasive pneumococcal disease. Journal of Infectious Diseases 2006; 193: 1487-1494. (Pubitemid 43794576)